Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 160

1.

IL-15 Trispecific Killer Engagers (TriKEs) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing In Vivo Expansion, and Enhanced Function.

Vallera DA, Felices M, McElmurry RT, McCullar V, Zhou X, Schmohl J, Zhang B, Lenvik A, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf D, Blazar BR, Miller JS.

Clin Cancer Res. 2016 Feb 4. pii: clincanres.2710.2015. [Epub ahead of print]

PMID:
26847056
2.

Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10year combined experience of 2 centres.

Ghosh A, Miller W, Orchard PJ, Jones SA, Mercer J, Church HJ, Tylee K, Lund T, Bigger BW, Tolar J, Wynn RF.

Mol Genet Metab. 2016 Jan 27. pii: S1096-7192(16)30010-5. doi: 10.1016/j.ymgme.2016.01.011. [Epub ahead of print]

PMID:
26832957
3.

Long-Term Cognitive and Functional Outcomes in Children with Mucopolysaccharidosis (MPS)-IH (Hurler Syndrome) Treated with Hematopoietic Cell Transplantation.

Kunin-Batson AS, Shapiro EG, Rudser KD, Lavery CA, Bjoraker KJ, Jones SA, Wynn RF, Vellodi A, Tolar J, Orchard PJ, Wraith JE.

JIMD Rep. 2016 Jan 30. [Epub ahead of print]

PMID:
26825088
4.

Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, Horowitz MM, Confer D, Deeg HJ, Eapen M.

Lancet Haematol. 2015 Sep;2(9):e367-75. doi: 10.1016/S2352-3026(15)00147-7. Epub 2015 Sep 2.

PMID:
26685770
5.

Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft.

Wagner JE Jr, Brunstein CG, Boitano AE, DeFor TE, McKenna D, Sumstad D, Blazar BR, Tolar J, Le C, Jones J, Cooke MP, Bleul CC.

Cell Stem Cell. 2016 Jan 7;18(1):144-55. doi: 10.1016/j.stem.2015.10.004. Epub 2015 Dec 5.

PMID:
26669897
6.

Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.

Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, McElroy AN, Starker CG, Lee C, Merkel S, Lund TC, Kelly-Spratt KS, Jensen MC, Voytas DF, von Kalle C, Schmidt M, Gabriel R, Hippen KL, Miller JS, Scharenberg AM, Tolar J, Blazar BR.

Mol Ther. 2015 Oct 27. doi: 10.1038/mt.2015.197. [Epub ahead of print]

PMID:
26502778
7.

Cross platform analysis of methylation, miRNA and stem cell gene expression data in germ cell tumors highlights characteristic differences by tumor histology.

Poynter JN, Bestrashniy JR, Silverstein KA, Hooten AJ, Lees C, Ross JA, Tolar J.

BMC Cancer. 2015 Oct 23;15:769. doi: 10.1186/s12885-015-1796-6.

8.

GSK3β inhibition activates the CDX/HOX pathway and promotes hemogenic endothelial progenitor differentiation from human pluripotent stem cells.

Kitajima K, Nakajima M, Kanokoda M, Kyba M, Dandapat A, Tolar J, Saito MK, Toyoda M, Umezawa A, Hara T.

Exp Hematol. 2016 Jan;44(1):68-74.e10. doi: 10.1016/j.exphem.2015.09.007. Epub 2015 Oct 23.

PMID:
26477526
9.

Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa.

Watt SA, Dayal JH, Wright S, Riddle M, Pourreyron C, McMillan JR, Kimble RM, Prisco M, Gartner U, Warbrick E, McLean WH, Leigh IM, McGrath JA, Salas-Alanis JC, Tolar J, South AP.

PLoS One. 2015 Sep 18;10(9):e0137639. doi: 10.1371/journal.pone.0137639. eCollection 2015.

10.

GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.

Koehn BH, Apostolova P, Haverkamp JM, Miller JS, McCullar V, Tolar J, Munn DH, Murphy WJ, Brickey WJ, Serody JS, Gabrilovich DI, Bronte V, Murray PJ, Ting JP, Zeiser R, Blazar BR.

Blood. 2015 Sep 24;126(13):1621-8. doi: 10.1182/blood-2015-03-634691. Epub 2015 Aug 11.

PMID:
26265697
11.

Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment.

Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J.

Cancer Immunol Immunother. 2015 Nov;64(11):1449-60. doi: 10.1007/s00262-015-1749-6. Epub 2015 Aug 7.

PMID:
26250807
12.

From Mesoderm to Mesodermatology: Bone Marrow Mesenchymal Cells Heal Skin Wounds.

Tolarova M, Tolar J.

Mol Ther. 2015 Aug;23(8):1283-4. doi: 10.1038/mt.2015.84. No abstract available.

PMID:
26227251
13.

Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Lund TC, Liegel J, Bejanyan N, Orchard PJ, Cao Q, Tolar J, Brunstein C, Wagner JE, Verneris MR, Weisdorf D.

Am J Hematol. 2015 Oct;90(10):892-6. doi: 10.1002/ajh.24111.

PMID:
26149534
14.

Gene editing toward the use of autologous therapies in recessive dystrophic epidermolysis bullosa.

Perdoni C, Osborn MJ, Tolar J.

Transl Res. 2016 Feb;168:50-8. doi: 10.1016/j.trsl.2015.05.008. Epub 2015 May 27. Review.

PMID:
26073463
15.

Sickle cell and silent spleen.

Tolar J.

Blood. 2015 Apr 23;125(17):2589-90. doi: 10.1182/blood-2015-03-633933.

PMID:
25907900
16.

Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.

Petrof G, Lwin SM, Martinez-Queipo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, Ofuya M, Peacock JL, Martinez AE, McGrath JA.

J Invest Dermatol. 2015 Sep;135(9):2319-21. doi: 10.1038/jid.2015.158. Epub 2015 Apr 23. No abstract available.

PMID:
25905587
17.

From marrow to matrix: novel gene and cell therapies for epidermolysis bullosa.

Webber BR, Tolar J.

Mol Ther. 2015 Jun;23(6):987-92. doi: 10.1038/mt.2015.47. Epub 2015 Mar 24. Review.

PMID:
25803200
18.

Placenta-based therapies for the treatment of epidermolysis bullosa.

Nevala-Plagemann C, Lee C, Tolar J.

Cytotherapy. 2015 Jun;17(6):786-95. doi: 10.1016/j.jcyt.2015.03.006. Epub 2015 Mar 18. Review.

PMID:
25795271
19.

The three-body problem of therapy with induced pluripotent stem cells.

Tolar J, McGrath JA.

Genome Med. 2015 Feb 20;7(1):15. doi: 10.1186/s13073-015-0141-7. eCollection 2015.

20.

Alternative donor transplant of benign primary hematologic disorders.

Tolar J, Sodani P, Symons H.

Bone Marrow Transplant. 2015 May;50(5):619-27. doi: 10.1038/bmt.2015.1. Epub 2015 Feb 9. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk